Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that ...

Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock ...

With a market cap of $234.7 billion, Amgen Inc. (AMGN) is a leading biotechnology company that discovers, develops, ...

The Dow Jones Industrial Average is climbing Wednesday morning with shares of UnitedHealth and Amgen seeing positive momentum for the blue-chip average. Shares of UnitedHealth and Amgen are ...

Sept 22 () - Amgen said on Tuesday its experimental drug to treat an ‌autoimmune disease that attacks the body's ‌moisture-producing glands met the main goal of reducing disease ​activity in a ...

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning. Amgen ...

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

Amgen drops after Novartis’ pelacarsen Phase 3 miss, pressuring olpasiran’s thesis amid patent cliffs. Click here to read an analysis of AMGN stock now.

Amgen stock recently closed at USD 385.65 on Nasdaq on September 18, 2026, leaving it close to the average analyst target near USD 387.69. Recent quarters have seen strong earnings momentum, ...

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.

Amgen stock was down 0.06 percent at Lang & Schwarz at 8:14 a.m. CEST on October 8, 2026. The pre-market price was EUR 368.38 ...